PTC Therapeutics of South Plainfield, NJ has inked a new deal to collaborate with CV Therapeutics on discovering new therapies for cardiovascular conditions. PTC gets $2 million up front and $8 million in loans. It stands to gain up to $335 million in milestone fees for the successful development of new therapies using its Gene Expression Modulation by Small-Molecules (GEMS) technology. Report